On October 6, 2020, Scribe Therapeutics introduced itself to the world with a promising collection of facts. It had a $20 million Series A, a collaboration with Biogen, and a plan to engineer tools for genetic medicine. One of its co-founders was Jennifer Doudna. The following day, Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry. For the people responsible for Scribe’s publicity, the calendar had become unusually cooperative.
Those people worked at Thermal, a San Francisco communications firm. In its account of the campaign, Thermal says the timing was deliberate: CRISPR seemed due for a Nobel, and perhaps this would be the year. It was a bet on an event the agency could neither arrange nor guarantee.
The tempting lesson is to time your announcement brilliantly. The more useful lesson lies in what Scribe had ready before Stockholm called. Financing, a pharmaceutical collaborator, and a scientific proposition gave reporters several reasons to pay attention. The award added another. Luck had somewhere to land.
Scribe’s launch
Funding + collaboration
The chemistry Nobel
Doudna + Charpentier
The molecule does not explain itself
Thermal occupies a particular corner of public relations: the place where an exciting biological idea must become intelligible to people outside the laboratory. Its clients work on gene editing, aging, AI in biology, and health technology. The website’s promise, “Impact Human Health™,” describes the destination. The agency’s actual work involves the sentences, interviews, images, and decisions that help explain the journey.
Consider the assignment from a reporter’s side. A company says its technology could change medicine. What, precisely, is different? What evidence exists? Which problem is it trying to solve? Why is this worth attention today? A technically accurate description may still leave every one of those questions unanswered. A catchy description can create an entirely different problem if it runs ahead of the evidence.
Thermal’s PR offering includes scientific narratives, media training, executive positioning, patent-related communications, and crisis management. These are related tasks. The explanation prepared for a launch needs to survive the interview, and the interview needs to survive scrutiny. A firm operating in this territory earns its place by understanding both the subject and the likely questions.
One story, several places to get it wrong
For Scribe, Thermal describes an assignment that extended across positioning, the brand and website, content, social media, and launch coverage. That breadth matters. A reporter who understands the announcement may still send readers to a confusing website. A founder may describe the technology one way while the company’s social accounts describe it another. Every handoff is an opportunity to lose the thread.
This helps explain a service menu that looks larger than the letters PR suggest. Thermal offers brand identity and messaging; articles, newsletters, and scientific posters; audience research and measurement; events and social programs. Its studio adds websites, animation, scientific visualization, and video. The practical proposition is coordination: the material can change shape as it moves between audiences while keeping its meaning.
The business model is a professional-services agency serving organizations and their leaders. A prospective client brings an assignment to scope. The useful purchasing question is therefore what work belongs in that assignment: a single announcement, an executive’s public presence, an explanation of a technical platform, or an ongoing communications program. Those are different jobs, even when they involve the same company.
- 01 / EvidenceWhat can the company substantiate?
- 02 / AudienceWho needs to understand it?
- 03 / ExpressionWhich story and format make it clear?
Editorial reading of Thermal’s services, not a proprietary agency framework.
When the argument is bigger than the client
A product launch has a date. A scientific reputation has a much longer calendar. Thermal says it has supported Doudna since 2016, with work spanning media, speaking, and public discussion of CRISPR’s responsible use. That relationship puts the agency near questions no launch announcement can settle: who should benefit from a technology, and how should society decide what to permit?
The firm’s account includes communications surrounding the 2018 announcement of gene-edited babies. Here, attention itself was hardly the scarce resource. The problem was what people would understand from it. A scandal involving one use of a technology could shape perceptions of a much wider field.
Thermal’s description of its CRISPR work includes coordinating coverage and developing opinion pieces and explanatory narratives. In May 2020, it announced a North America SABRE Award for Crisis Management. That is recognition of communications work. The distinction is worth keeping: the science belongs to the scientists, and the public argument is something a communications team helps them conduct.
Aging research comes with extra baggage
Longevity presents a different difficulty. The word arrives carrying dreams about extra years, anxieties about decline, and a considerable supply of extravagant promises. Thermal’s own writing on the field recognizes the tension between hope and hype. Its clients include Retro Biosciences and BioAge, but their stories require more precision than a shared label provides.
Retro describes a mission to add ten years to healthy human lifespan. Thermal’s case study frames its role around communicating a company developing therapies for diseases associated with aging. BioAge’s case study is more explicit about the communications mechanics: establish a scientific identity grounded in longitudinal human data, develop CEO Kristen Fortney’s public voice, and coordinate media work around financing and clinical milestones.
That approach suggests a useful editorial discipline. Begin with the particular research and the particular claim. Explain the people and methods behind it. Then place it in the larger conversation. If the grand ambition does all the talking, the reader has little left with which to judge the company.
“They get the science and how to translate in order to share its promise with the world.”
Joe Betts-LaCroix / CEO, Retro Biosciences
Client testimonial published by Thermal
Two kinds of healthcare experience
The founders’ backgrounds help explain the combination. CEO Kaustuva Das’s biography describes more than twenty years in corporate and agency communications, including healthcare, biopharma, and digital health. Co-founder and Chief Experience Officer Brenna Sweeney brings healthcare marketing experience that spans positioning, product launches, patient engagement, regulatory issues, and commercialization.
That pairing connects the public story to the practical experience of bringing a health offering to people. Thermal’s stated workplace values also put an emphasis on reading papers, asking questions, and maintaining scientific accuracy. Its team includes a Director of AI Narrative & Strategy, Fay Lin. The title is a small sign of where the agency sees work to do: explaining an increasingly technical overlap between computing and biology.
In market terms, Thermal is a specialist agency. The alternative could be another life-sciences communications firm, a healthcare team at a larger agency, or an internal hire. The case for a specialist is strongest when explaining the subject and anticipating its sensitivities are substantial parts of the job. A simple local promotion asks for a different set of strengths.
Copy the preparation, not the Nobel
Return to that October launch. Its financial number can easily distract from the service being discussed. Scribe’s $20 million was company financing. It was not Thermal’s fee, and it does not measure what the publicity was worth. The same care applies when reading agency claims about the amount of financing announced: communicating a transaction and supplying the capital are different contributions.
What a founder can borrow is more concrete. Assemble the evidence before chasing the headline. Make the website, spokesperson, and announcement explain the same proposition. Know which audience each piece serves. Give reporters enough substance that the story remains useful if the hoped-for outside event never happens.
There are limits to the approach. An elegant explanation cannot supply missing evidence, and a crowded news calendar does not owe a company attention. The Scribe example is persuasive because a credible announcement existed before the lucky day. Thermal’s most interesting work sits in that preparation: making a complicated subject ready for the moment someone finally asks about it.